(NASDAQ: MRKR) Marker Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 48.02%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.33%.
Marker Therapeutics's earnings in 2025 is -$14,298,034.On average, 5 Wall Street analysts forecast MRKR's earnings for 2025 to be -$31,292,125, with the lowest MRKR earnings forecast at -$42,483,128, and the highest MRKR earnings forecast at -$18,907,326. On average, 4 Wall Street analysts forecast MRKR's earnings for 2026 to be -$46,853,154, with the lowest MRKR earnings forecast at -$80,391,149, and the highest MRKR earnings forecast at -$10,329,002.
In 2027, MRKR is forecast to generate -$25,764,983 in earnings, with the lowest earnings forecast at -$45,914,457 and the highest earnings forecast at -$3,851,492.